Quick Answer
Zenas BioPharma, Inc. reported Stockholders Equity of $242.14 million for the year ending 2025.
- Zenas BioPharma, Inc. showed a decrease of -22.5% in Stockholders Equity from 2024 to 2025.
- This data is from Zenas BioPharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: -$210.65 million | Q2 2023: -$238.85 million | Q3 2023: -$202.23 million | Q1 2024: -$252.50 million | Q2 2024: -$288.78 million | Q3 2024: $359.44 million | Q1 2025: $284.32 million | Q2 2025: $239.63 million | Q3 2025: $196.43 million.
- Over the full 4 years of available data (2022 to 2025), Zenas BioPharma, Inc.'s Stockholders Equity has grown by 225.9%.
- Historical annual values: Fiscal year 2025: $242.14 million | Fiscal year 2024: $312.46 million | Fiscal year 2023: -$225.72 million | Fiscal year 2022: -$192.29 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: